Abstract 2690
Background
GIST in older adults and in children are well-known entities, but this is not the case for AYA patients with GIST. Typically, GIST in children (70% female) rarely show mutations in KIT or platelet-derived growth factor receptor (PDGFR) (<15%), are often Succinate Dehydrogenase (SDH) deficient, are almost always located in the stomach (90%) and have a relatively indolent course of disease. The typical adult GIST (about 50% female) has mutations in KIT (75%) or PDGFR (15%), stomach as main location and an overall 5-years survival of 65% (SEER data). As data on AYA with GIST are very limited, we aimed to study the clinical and genetic characteristics and outcome of this specific group.
Methods
AYA GIST patients (18-40 years at diagnosis) diagnosed between 2009-2019 and registered in the Dutch GIST Registry (DGR) were included. Patients without mutations in KIT/PDGFR/BRAF and SDH deficiency (by immunohistochemistry) were considered quadruple wildtype (WT). Overall survival (OS) was estimated using Kaplan-Meier method. Furthermore, two subgroups were compared: 18-29 years vs. 30-40 years (Chi-square, Fisher’s exact, Mann-Whitney U test).
Results
From 1011 patients in the DGR, 52 AYA patients (5%) were identified: 54% male, median age 35 years. Main primary tumor locations were stomach (46%) and small intestine (46%). Four AYA patients had a known genetic predisposition: 2 Neurofibromatosis 1 (NF1), 1 Carney Triad, 1 KIT exon 11 germline mutation. GIST genetic profiles were reported as KIT mutation 64%, PDGFR mutation 6%, KIT/PDGFR WT 6%, quadruple WT 8%, SDH deficient 6% and NF1 associated 4%. At diagnosis, 42% had high-risk GIST and 13% metastatic disease.
With a median follow-up of 43 months (0-113), median OS for all patients was 8.9 years with a 5-year survival of 85%. No significant differences were found between the two subgroups with regard to gender, location, size, morphology, risk classification and mutation status.
Conclusions
GIST presenting at AYA age is rare. AYA GIST differ from the well-known paediatric GIST, but are also not fully similar to the typical adult GIST. In our series a remarkable high percentage of small intestine GIST and high-risk tumours were observed, 30% non-KIT/PDGFR mutations and a relatively good survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Netherlands Cancer Institute.
Funding
An unrestricted research grant for the Dutch GIST Registry was received from Novartis, Bayer and Pfizer.
Disclosure
I.M.E. Desar: Research grant / Funding (institution): Novartis; Advisory / Consultancy, advisory board: Eisai; Advisory / Consultancy, advisory board: Lilly. R.H.J. Mathijssen: Research grant / Funding (institution), Travel / Accommodation / Expenses: Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Boehringer; Research grant / Funding (institution): Cristal Therapeutics; Honoraria (institution), Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pamgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi; Honoraria (institution): Servier. N. Steeghs: Research grant / Funding (institution): AstraZeneca/MedImmune; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): AB science; Research grant / Funding (institution): Deciphera; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Merck Sharp & Dohme; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Merus. W.T.A. van der Graaf: Research grant / Funding (institution): Novartis; Advisory / Consultancy: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
5107 - Tolerability of PCV in Low Grade Glioma: a Real World Experience
Presenter: Razia Aslam
Session: Poster Display session 1
Resources:
Abstract
6171 - Molecular EGFR/PD-L1 profile of glioblastoma: Hints for therapeutic strategies
Presenter: Wojciech Szopa
Session: Poster Display session 1
Resources:
Abstract
4418 - Role of Intraoperative MRI (iMRI) in neurosurgery, potential imaging tool for maximizing gross total resection (GTR) rate of CNS tumours.
Presenter: Shweta Wadhwa
Session: Poster Display session 1
Resources:
Abstract
4791 - Tumor related impairments of neurocognitive functions in patients with brain metastases
Presenter: Lei Wen
Session: Poster Display session 1
Resources:
Abstract
5372 - Is radiation therapy influencing Alzheimer’s in Brain and Head and Neck Cancers?
Presenter: Anas Saad
Session: Poster Display session 1
Resources:
Abstract
2329 - Mature Treatment Results of 120 Cases of Acoustic Neuroma Treated with Cyberknife at a single institution.
Presenter: Shawn Malone
Session: Poster Display session 1
Resources:
Abstract
3207 - A phase II/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: the STELLAR study
Presenter: Cyrillo Brahm
Session: Poster Display session 1
Resources:
Abstract
3589 - CNS penetration and Preliminary Efficacy of Sacutizumab Govitecan in Breast Brain Metastasis and Glioblastoma: A Surgical Study
Presenter: Andrew Brenner
Session: Poster Display session 1
Resources:
Abstract
1969 - Wedge resection with omission of lymph node dissection as an optional treatment strategy in octogenarians or older with early stage non-small cell lung cancers
Presenter: Takahiro Mimae
Session: Poster Display session 1
Resources:
Abstract
5116 - Characterization of lung tumorspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer
Presenter: Alejandro Herreros Pomares
Session: Poster Display session 1
Resources:
Abstract